What we found on the web about MedImmune
MedImmune - Wikipedia, the free encyclopedia
MedImmune, LLC, headquartered in Gaithersburg, Maryland, became a wholly owned subsidiary of AstraZeneca in 2007. Since being acquired, MedImmune has remained a Maryland-based ...
MedImmune, Inc. v. Genentech, Inc. - Wikipedia, the free encyclopedia
MedImmune, Inc. v. Genentech, Inc., 549 U.S. 118 was a decision by the Supreme Court of the United States involving patent law. It arose from a lawsuit filed by MedImmune which ...
MEDIMMUNE, INC. v. GENENTECH, INC.
Petitioner MedImmune, Inc. ... for Plantiff-Appellant MedImmune, Inc. in Nos. ... Like Gen-Probe, MedImmune filed an action seeking a declaratory judgment that: ...
MedImmune Inc.| Post 200: Top Businesses in D.C., Maryland and Virginia ...
MedImmune Inc. is the most successful biotechnology company in the Washington area, with several products on the market and sales of more than $1 billion.
SUPREME COURT OF THE UNITED STATES
supreme court of the united states syllabus medimmune, inc. v . genentech, inc., et al . certiorari to the united states court of appeals for the federal circuit no. 05-608.
BioSpace - MedImmune News, Search Jobs, Events
MedImmune is the worldwide biologics business for the AstraZeneca Group. The company has approximately 3,000 employees worldwide and is headquartered in Gaithersburg, Maryland with ...
MedImmune | Terms & Conditions
MedImmune, Inc. provides the materials on its website for general informational, educational, and disease awareness purposes. Although accessible by others, the website and its ...
BioSpace - MedImmune, LLC News, Search Jobs, Events
MedImmune is the worldwide biologics business for the AstraZeneca Group. ... Fourteen Abstracts Featuring MedImmune, Inc.'s Influenza and ... MedImmune, Inc. ...
MedImmune Receives FDA Complete Response Letter on Motavizumab
MedImmune Receives FDA Complete Response Letter on Motavizumab ... AstraZeneca today announced that MedImmune, its wholly owned biologics business, has received a Complete Response ...
MEDIMMUNE, INC. v. GENENTECH, INC.
Justice Scalia, Opinion of the Court. NOTICE: This opinion is subject to formal revision before publication in the preliminary print of the United States Reports.
Patent Law Blog (Patently-O): MedImmune v. Genentech -- Licensee's ...
MedImmune v. Genentech (Supreme Court 2006). Earlier this year, the Supreme Court granted MedImmune's petition for certiorari to determine when a patent licensee can ...
After Long Resistance, MedImmune Seeks Buyer
MedImmune , the region's most successful biotechnology firm, said yesterday that it is exploring options to sell itself, perhaps to a major pharmaceutical company, marking an ...
MedImmune, Inc. v. Genentech, Inc. - Wikipedia, the free encyclopedia
MedImmune was a licensee of the later Cabilly patent, but argued that the term ... Operation Restoration: How can Patent Holders protect themselves from MedImmune" ...
Entry added by Creative Administrator
Creative Administrator also edited:
Here is what users have to say about MedImmune

Advert: date=October 2009

Welcome to CWAnswers

CWAnswers is your guide to the sprawling world wide web. The directory aims to provide a useful guide made by users. You can share your knowledge as well - simply register and edit your first entry. For questions just contact the team at support - at - cwanswers.com.

Weblinks

Top 10

Things you find nowhere else.

Comments

You must be logged in to post a comment.

No comments yet on this topic. Be the first one!
These recent articles mention MedImmune
Companies start initial work on pandemic vaccine 
Reuters via Yahoo! UK & Ireland News
Manufacturers have taken the first preparatory steps in developing a vaccine against a new strain of flu that has killed up to 149 people in Mexico and threatens to become a pandemic.
Gravy or Turkey From the FDA?
MSNBC
As one of the first benefits from acquiring MedImmune's pipeline last year, AstraZeneca (NYSE: AZN) will get a shot at approval of its respiratory syncytial virus (RSV) prophylactic, motavizumab, around Nov. 30. Unfortunately, the drug, whi...
Research and Markets: Biopharma Quarter: Key Trends and Events of the Fourth Quarter of 2008 Focuses on the Companies ...
Business Wire via Yahoo! Finance
DUBLIN----Research and Markets has announced the addition of Decision Resources, Inc.'s new report "Biopharma Quarter: Key Trends and Events of the Fourth Quarter of 2008" to their offering.
Companies start initial work on pandemic vaccine
AlertNet
Source: Reuters * Genetic code of virus available, virus samples awaited * Production process will take months * WHO will only call for new vaccine if pandemic imminent * Making pandemic vaccine means ...
AstraZeneca names Fante president of US business
MSN MoneyCentral
WILMINGTON, Del. (AP) - British pharmaceutical company AstraZeneca PLC said Tuesday it has named Rich Fante president of its U.S. business. Fante replaces Tony Zook, who was recently named president of MedImmune, a biologics business owned ...